-
公开(公告)号：US20230110095A1
公开(公告)日：2023-04-13
申请号：US17807731
申请日：2022-06-20
发明人： Xueqin Lu , Zhuo Mu , Shengjun Wang , Yanchun Du
IPC分类号： C12N15/113 , A61K47/54 , A61K47/55 , A61P31/20
摘要： The present invention relates to a novel compound and application thereof in the inhibition of HBV gene expression. The structure of the compound comprises an interfering nucleic acid for inhibiting HBV gene expression, transition points, and delivery chains of the interfering nucleic acid. By means of the delivery chains, two or three N-acetylgalactosamines can be introduced to an antisense strand 3′ end of such siRNA, and two or one N-acetylgalactosamine can be correspondingly introduced to a sense strand 5′ end, the total number of the introduced N-acetylgalactosamines being four. In vitro and in vivo pharmacological experiments prove that such a novel compound can continuously and efficiently inhibit HBV gene expression.
-
公开(公告)号：US11840691B2
公开(公告)日：2023-12-12
申请号：US17807731
申请日：2022-06-20
发明人： Xueqin Lu , Zhuo Mu , Shengjun Wang , Yanchun Du
IPC分类号： C12N15/113 , A61K47/54 , A61K47/55 , A61P31/20
CPC分类号： C12N15/1131 , A61K47/545 , A61K47/55 , A61P31/20 , C12N2310/11 , C12N2310/14
摘要： The present invention relates to a novel compound and application thereof in the inhibition of HBV gene expression. The structure of the compound comprises an interfering nucleic acid for inhibiting HBV gene expression, transition points, and delivery chains of the interfering nucleic acid. By means of the delivery chains, two or three N-acetylgalactosamines can be introduced to an antisense strand 3′ end of such siRNA, and two or one N-acetylgalactosamine can be correspondingly introduced to a sense strand 5′ end, the total number of the introduced N-acetylgalactosamines being four. In vitro and in vivo pharmacological experiments prove that such a novel compound can continuously and efficiently inhibit HBV gene expression.
-
公开(公告)号：US11623938B2
公开(公告)日：2023-04-11
申请号：US17790191
申请日：2020-09-02
发明人： Kunyuan Cui , Shengjun Wang , Yanchun Du
摘要： The present invention belongs to the field of biomedicine, specifically relates to the field of targeting medicine. More specifically, the present invention relates to a liver-targeting compound having thyroid hormone receptor agonist characteristics and a pharmaceutical composition thereof. The compound is a compound represented by formula (1). The compound can be used for treating and/or preventing diseases caused by thyroid hormone dysregulation, and can also effectively reduce lipids in plasma and liver cells.
-
-
搜索结果
3 条记录 (耗时 0.011 秒)
